OptimizeRx (OPRX) is a stock that many stripes of investors could love. They appear to be a small cap company in a solid uptrend with a history of double digit revenue growth.
And the most exciting part is that they look to be an up and coming telehealth name akin to Teladoc (TDOC) but with the caveat that they have largely flown under the radar of big institutional investors.
Things are unfortunately a bit more complicated at OptimizeRx, with the largest issue being that we have very real reasons to be concerned with the accuracy of OPRX’s financial statements. But first I will parse OPRX’s flowery description of their business and demonstrate that they are largely a simple advertising company that provides digital coupons.
Clipping coupons does not = the next Teladoc
Below is language from OPRX’s latest 10-k describing their business:
The type of responses that we have seen in recent IPOs point towards not only ample liquidity in the system but more importantly towards investor sentiment, Prasanna Pathak, Head of Equity, Taurus Mutual Fund, said in an interview with Moneycontrol’s Kshitij Anand.
Q) US Fed plans to keep interest rates low for a long time. What is the kind of impact it will have on emerging markets like India as well as the currency?
A) The plan to keep the interest rates low for a long time, indicates that the US Fed is skeptical of demand revival in the economy and hence the revival of inflation in the short to medium term.
Though this does point to a weak economic recovery. The low-interest rates coupled with the central